Xadago Европейски съюз - български - EMA (European Medicines Agency)

xadago

zambon spa - сафинамид метансулфонат - Паркинсонова болест - Антипаркинсонови лекарства - xadago е показан за лечение на възрастни пациенти с идиопатична Паркинсонова болест (Пд) като допълнителна терапия към стабилна доза на леводопа (l-dopa) самостоятелно или в комбинация с други pd лекарствени продукти в средата-стадий колебания пациенти.

Pifeltro Европейски съюз - български - EMA (European Medicines Agency)

pifeltro

merck sharp & dohme b.v. - doravirine - ХИВ инфекции - Антивирусни средства за системно приложение - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

Lacosamide UCB Европейски съюз - български - EMA (European Medicines Agency)

lacosamide ucb

ucb pharma s.a. - лакозамид - Епилепси, частично - Противоэпилептические средства, - Производител УКБ включен като монотерапии и допълнителна терапия при лечение на парциальных пристъпи С или без вторична генерализации при възрастни, юноши и деца от 4 години с епилепсия.

Klisyri Европейски съюз - български - EMA (European Medicines Agency)

klisyri

almirall, s.a. - tirbanibulin - Кератоза, актинична - Антибиотици и химиотерапевтици за дерматологично приложение - klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (olsen grade 1) of the face or scalp in adults.

Bimzelx Европейски съюз - български - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a.   - bimekizumab - псориазис - Имуносупресори - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Sitagliptin SUN Европейски съюз - български - EMA (European Medicines Agency)

sitagliptin sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Ertapenem SUN Европейски съюз - български - EMA (European Medicines Agency)

ertapenem sun

sun pharmaceutical industries (europe) b.v. - етапенем натрий - Бактериални инфекции - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 и 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. Трябва да се вземат предвид официалните препоръки за правилното използване на антибактериални агенти.

Teriparatide Sun Европейски съюз - български - EMA (European Medicines Agency)

teriparatide sun

sun pharmaceutical industries europe b.v. - терипаратид - osteoporosis; osteoporosis, postmenopausal - Калциева хомеостаза - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Sitagliptin / Metformin hydrochloride Sun Европейски съюз - български - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. тройно комбинирано лечение) като допълнение към диета и упражнения при пациенти, недостатъчно контролирани за тяхното максимално переносимой дозата на метформина и сульфонилмочевины. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Ebglyss Европейски съюз - български - EMA (European Medicines Agency)

ebglyss

almirall, s.a. - lebrikizumab - Дерматит, Атопич - Други дерматологични препарати - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.